Specifically, investigations based on computational approaches which can quantify indications of diagnostic, therapeutic, and prognostic biomarkers pertaining to HER2+ BC can accelerate drug development, drug repositioning, and identification of effective drug combination for managing the disease (2, 68–70). Here, ERBB2 is linked to breast cancer.